Suppr超能文献

自身免疫性胆道疾病的临床管理。

Clinical management of autoimmune biliary diseases.

机构信息

Cholestatic Liver Diseases Study Group, Division of Gastroenterology and Hepatology Mayo Clinic, Rochester, MN, USA.

出版信息

J Autoimmun. 2013 Oct;46:88-96. doi: 10.1016/j.jaut.2013.06.014. Epub 2013 Jul 13.

Abstract

Autoimmune biliary disease is an umbrella term that encompasses several distinct entities such as primary sclerosing cholangitis, primary biliary cirrhosis, autoimmune hepatitis and overlap syndromes. The general approach to the diagnosis of these disorders involves investigating symptomatic patients presenting with a cholestatic biochemical profile. Asymptomatic patients are often diagnosed during investigation of other accompanying or discrete diseases. The distinction between the various entities is necessary for directing clinical management in this group of patients with an underlying autoimmune pathophysiology. Goals of management comprise treating symptoms, preventing complications and suppressing the underlying pathogenetic processes. Liver transplantation plays a vital role in the management of this group of patients and has shown a dramatic improvement in outcomes. Medical therapies such as ursodeoxycholic acid have shown mixed effects with excellent outcomes in primary biliary cirrhosis and less impressive results in primary sclerosing cholangitis. In this manuscript we aim to discuss in detail the management of these autoimmune biliary disorders and describe the effects of different therapies on outcomes on the different subsets of patients.

摘要

自身免疫性胆道疾病是一个总称,包括几种不同的实体,如原发性硬化性胆管炎、原发性胆汁性肝硬化、自身免疫性肝炎和重叠综合征。这些疾病的诊断方法通常涉及对出现胆汁淤积性生化特征的有症状患者进行调查。无症状患者通常在对其他伴随或离散疾病进行调查时被诊断出来。区分这些实体对于指导这群具有潜在自身免疫病理生理学的患者的临床管理是必要的。管理目标包括治疗症状、预防并发症和抑制潜在的发病机制。肝移植在这群患者的管理中起着至关重要的作用,并且已经显示出在结果方面的显著改善。熊去氧胆酸等医学疗法显示出混合效应,在原发性胆汁性肝硬化中效果极佳,而在原发性硬化性胆管炎中效果则不那么显著。在本文中,我们旨在详细讨论这些自身免疫性胆道疾病的管理,并描述不同疗法对不同亚组患者的治疗效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验